Stock BGBIO BERGENBIO ASA
Add to a list
To use this feature you must be a member
Log inSign up

Financials BerGenBio ASA

Equities

BGBIO

NO0010650013

Biotechnology & Medical Research

Market Closed - Oslo Bors
Other stock markets
 10:45:00 2024-04-26 am EDT 		5-day change 1st Jan Change
0.1504 NOK -3.59% Intraday chart for BerGenBio ASA -7.96% -45.90%
Mar. 20 Bergenbio Announces Initiation of Phase 2A in First Line Non-Small Lung Cancer Patients with A STK11 Mutation CI
Feb. 14 BerGenBio ASA Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Capitalization 1 1,461 1,487 2,810 1,794 662.3 587.9 587.9 -
Enterprise Value (EV) 1 1,100 1,234 2,089 1,358 511.8 591 658.7 871.8
P/E ratio -7.42 x -7.1 x -9.39 x -5.76 x -2.19 x -2.14 x -2.08 x -1.79 x
Yield - - - - - - - -
Capitalization / Revenue 626 x 167 x 4,675 x 2,242 x 1,703 x 2,111 x - -
EV / Revenue 471 x 139 x 3,477 x 1,698 x 1,316 x 1,670 x - -
EV / EBITDA -5.66 x -6.06 x -8.03 x -4.34 x -1.68 x -3.08 x -3.38 x -3.89 x
EV / FCF -5.89 x - -8.92 x -4.45 x -1.8 x -1.91 x - -
FCF Yield -17% - -11.2% -22.5% -55.7% -52.4% - -
Price to Book 4.22 x - 3.6 x 4.64 x 7.48 x 5.86 x -21.3 x -2.5 x
Nbr of stocks (in thousands) 54,711 61,077 87,260 88,455 88,661 3,908,712 3,908,712 -
Reference price 2 26.70 24.35 32.20 20.28 7.470 0.1504 0.1504 0.1504
Announcement Date 2/12/19 2/11/20 2/10/21 2/16/22 2/16/23 2/14/24 - -
1NOK in Million2NOK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Net sales 1 2.335 8.9 0.601 0.8 0.389 0.354 - -
EBITDA 1 -194.3 -203.6 -260.4 -313.2 -304.8 -191.6 -194.8 -224.2
EBIT 1 -194.5 -204.4 -261.1 -314.5 -305.6 -191.8 -195.1 -224.6
Operating Margin -8,331.43% -2,296.63% -43,442.76% -39,312.5% -78,569.41% -54,186.16% - -
Earnings before Tax (EBT) 1 -191.7 -199.3 -257 -309.4 -302.1 -190.4 -194.7 -233.7
Net income 1 -191.7 -199.3 -257 -309.4 -302.1 -190.4 -194.7 -233.7
Net margin -8,209.85% -2,239.08% -42,766.89% -38,670.5% -77,666.32% -53,785.59% - -
EPS 2 -3.600 -3.430 -3.430 -3.520 -3.410 -0.1300 -0.0724 -0.0841
Free Cash Flow 1 -186.9 - -234.4 -305.3 -285 -241 - -
FCF margin -8,005.74% - -38,994.51% -38,163.87% -73,260.41% - - -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share 2 - - - - - - - -
Announcement Date 2/12/19 2/11/20 2/10/21 2/16/22 2/16/23 2/14/24 - -
1NOK in Million2NOK
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2019 S1 2020 S1 2021 Q2 2021 S1 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 S1 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 S1 2024 Q3 2024 Q4
Net sales 1 8.682 - - - - 0.8 - - - - 0.389 - - - 0.354 - - - - -
EBITDA 1 - - -91.97 - -71.08 -67.01 -78.25 -87.92 - -62.29 -76.29 -72.42 - -27.98 -43.44 -46.2 -48.28 -94.5 -51.9 -56.5
EBIT 1 - - -92.31 -175.7 -71.42 -67.3 -78.57 -88.2 -166.8 -62.43 -76.4 -72.42 - - -43.54 - - - - -
Operating Margin - - - - - -8,412.5% - - - - -19,640.87% - - - -12,300.28% - - - - -
Earnings before Tax (EBT) 1 -97.1 -115.8 -88.86 -170.1 -70.5 -68.77 -81.07 -84.07 -165.1 -59.8 -77.19 -72 - -27.93 -41.64 -45.1 -47.28 -92.3 -51.6 -57.6
Net income 1 -97.1 -115.8 -88.86 -170.1 -70.5 -68.77 -81.07 -84.07 -165.1 -59.8 -77.19 -72 -48.84 -27.93 -41.64 -45.1 -47.3 -92.3 -51.6 -57.6
Net margin -1,118.38% - - - - -8,595.75% - - - - -19,842.93% - - - -11,761.3% - - - - -
EPS 2 -1.760 -1.590 -1.020 -1.940 -0.8000 -0.7800 -0.9200 -0.9500 -1.860 - -0.8700 - -0.1500 -0.0100 -0.0200 -0.0200 -0.0200 -0.0300 -0.0200 -0.0200
Dividend per Share - - - - - - - - - - - - - - - - - - - -
Announcement Date 8/19/19 8/17/20 8/17/21 8/17/21 11/16/21 2/16/22 5/24/22 8/23/22 8/23/22 11/15/22 2/16/23 6/22/23 8/23/23 11/14/23 2/14/24 - - - - -
1NOK in Million2NOK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Net Debt 1 - - - - - - 70.9 284
Net Cash position 1 360 254 720 436 151 156 - -
Leverage (Debt/EBITDA) - - - - - - -0.3638 x -1.266 x
Free Cash Flow 1 -187 - -234 -305 -285 -241 - -
ROE (net income / shareholders' equity) -55.8% - -57.8% -58.7% -128% -176% - -
ROA (Net income/ Total Assets) -50.3% - -51% -52.1% -97.9% -112% - -
Assets 1 381.5 - 504.3 594.2 308.5 170.5 - -
Book Value Per Share 2 6.330 - 8.950 4.370 1.000 0.0500 -0.0100 -0.0600
Cash Flow per Share - - - - - - - -
Capex 1 0.23 - 0.07 - 0.3 0.31 0.33 0.35
Capex / Sales 9.76% - 11.15% - 76.86% - - -
Announcement Date 2/12/19 2/11/20 2/10/21 2/16/22 2/16/23 2/14/24 - -
1NOK in Million2NOK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
2
Last Close Price
0.1504 NOK
Average target price
0.7667 NOK
Spread / Average Target
+409.75%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
BERGENBIO ASA Stock BerGenBio ASA
-45.90% 53.23M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. BGBIO Stock
  4. Financials BerGenBio ASA